+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Digital Dose Inhaler Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896110
  • Report
  • June 2020
  • Region: Global
  • 112 Pages
  • Mordor Intelligence

FEATURED COMPANIES

  • AstraZeneca Plc
  • Glenmark Pharmaceuticals
  • Koninklijke Philips N.V.
  • Novartis International AG
  • Opko Health, Inc.
  • Propeller Health
The digital dose inhaler market is anticipated to grow with a CAGR of above 13.3% during the forecast period. The major factors attributing to the growth of the digital dose inhaler market include the rising prevalence of chronic respiratory diseases and the growing demand for technology-enabled features of the respiratory devices.

Soaring geriatric populations suffering from respiratory disorders and favorable reimbursement policies also play a significant role in the growth of the market. According to the report of the Global Asthma Network 2018, around 339 million people are affected by Asthma, and the prevalence is rising. The rising prevalence of respiratory diseases globally is pushing the market growth. However, the high cost of the inhalers is the constraint to the growth of the market.

Key Market Trends

Dry Powder Inhalers (DPI) are Expected to Hold a Major Share in the Growth of the Market

Dry powder inhalers are devices that deliver medication to the lungs in the form of a dry powder. The major factors attributing to the growth of the dry powder inhaler segment are the prevalence of chronic respiratory diseases like COPD, Asthma, etc. and growing demand for technology-enabled features of the respiratory devices. Problems related to the occurrences of drug irritation caused by the existence of propellant components, such as chlorofluorocarbons (CFCs) in MDI, have boosted the usage of the DPIs, with lesser irritant impacts while providing therapeutic efficacy as MDIs.Hence the DPIs are called the green inhalers.

Though the MDIs hold a significant market share, the adoption of the manufacturing of DPIs by the health care providers increases production in the coming years.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall digital dose inhaler market throughout the forecast period. The growth is credited to the meticulous research and development programs, increasing awareness regarding the presently available, hi-tech respiratory devices. Also, an increase in the prevalence of respiratory conditions among both the pediatric and the elderly population will further benefit market growth.

According to the Asthma and Allergy Foundation of America (AAFA), every day, 10 Americans die from asthma, and 3,564 people died from asthma in 2017. With the increasing prevalence of chronic respiratory diseases, the digital dose inhaler market in the region grows proportionally.

Competitive Landscape

The digital dose inhaler market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market include Glenmark Pharmaceuticals Ltd., AstraZeneca Plc, Novartis International AG, Propeller Health, Philips Respironics, Opko Health, Inc., and Teva Pharmaceutical Industries Ltd.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca Plc
  • Glenmark Pharmaceuticals
  • Koninklijke Philips N.V.
  • Novartis International AG
  • Opko Health, Inc.
  • Propeller Health

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Chronic Respiratory Diseases
4.2.2 Soaring Geriatric Population Afflicted With Respiratory Disorders
4.2.3 Increasing R&D Investment for Technological Improvement and Device Miniaturization
4.3 Market Restraints
4.3.1 High Cost of the Devices
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Dry Powder Inhalers
5.1.2 Metered Dose Inhalers
5.2 By Application
5.2.1 Chronic Obstructive Pulmonary Disease
5.2.2 Asthma
5.2.3 Others
5.3 By Type
5.3.1 Branded
5.3.2 Generic
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Glenmark Pharmaceuticals
6.1.2 Novartis International AG
6.1.3 AstraZeneca Plc
6.1.4 Propeller Health
6.1.5 Koninklijke Philips N.V.
6.1.6 Opko Health, Inc.
6.1.7 Teva Pharmaceutical Industries Ltd.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Glenmark Pharmaceuticals
  • Novartis International AG
  • AstraZeneca Plc
  • Propeller Health
  • Koninklijke Philips N.V.
  • Opko Health, Inc.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...